| Dr Gregory Scott Dibelius, MD | |
|
8906 135th St Ste 2t, Jamaica, NY 11418-2828 | |
| (718) 206-7110 | |
| Not Available |
| Full Name | Dr Gregory Scott Dibelius |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 13 Years |
| Location | 8906 135th St Ste 2t, Jamaica, New York |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1447559026 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207YS0123X | Otolaryngology - Facial Plastic Surgery | ME131734 (Florida) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Nassau University Medical Center | East meadow, NY | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Tjh Medical Services Pc | 8527960533 | 194 |
News Archive
Men with advanced prostate cancer receiving androgen-deprivation therapy may be better off being treated intermittently rather than on a continuous basis, show study findings.
The Wall Street Journal looks at a lawsuit that is revealing just how doctors - and thusly consumers - are influenced by device makers. And Google moves into the emergency room.
Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.
Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.
› Verified 1 days ago
| Entity Name | Brookdale Hospital Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1720028772 PECOS PAC ID: 4284545799 Enrollment ID: O20031120000600 |
News Archive
Men with advanced prostate cancer receiving androgen-deprivation therapy may be better off being treated intermittently rather than on a continuous basis, show study findings.
The Wall Street Journal looks at a lawsuit that is revealing just how doctors - and thusly consumers - are influenced by device makers. And Google moves into the emergency room.
Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.
Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.
› Verified 1 days ago
| Entity Name | Tjh Medical Services Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1184670465 PECOS PAC ID: 8527960533 Enrollment ID: O20040121000802 |
News Archive
Men with advanced prostate cancer receiving androgen-deprivation therapy may be better off being treated intermittently rather than on a continuous basis, show study findings.
The Wall Street Journal looks at a lawsuit that is revealing just how doctors - and thusly consumers - are influenced by device makers. And Google moves into the emergency room.
Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.
Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.
› Verified 1 days ago
| Entity Name | Flushing Hospital & Medical Center |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1548217763 PECOS PAC ID: 2668367483 Enrollment ID: O20040219000415 |
News Archive
Men with advanced prostate cancer receiving androgen-deprivation therapy may be better off being treated intermittently rather than on a continuous basis, show study findings.
The Wall Street Journal looks at a lawsuit that is revealing just how doctors - and thusly consumers - are influenced by device makers. And Google moves into the emergency room.
Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.
Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.
› Verified 1 days ago
| Entity Name | Jamaica Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477505220 PECOS PAC ID: 2264324334 Enrollment ID: O20040427001519 |
News Archive
Men with advanced prostate cancer receiving androgen-deprivation therapy may be better off being treated intermittently rather than on a continuous basis, show study findings.
The Wall Street Journal looks at a lawsuit that is revealing just how doctors - and thusly consumers - are influenced by device makers. And Google moves into the emergency room.
Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.
Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Gregory Scott Dibelius, MD 635 Madison Ave Fl 14, New York, NY 10022-1009 Ph: (212) 518-1036 | Dr Gregory Scott Dibelius, MD 8906 135th St Ste 2t, Jamaica, NY 11418-2828 Ph: (718) 206-7110 |
News Archive
Men with advanced prostate cancer receiving androgen-deprivation therapy may be better off being treated intermittently rather than on a continuous basis, show study findings.
The Wall Street Journal looks at a lawsuit that is revealing just how doctors - and thusly consumers - are influenced by device makers. And Google moves into the emergency room.
Arena Pharmaceuticals, Inc. announced today that the European Medicines Agency (EMA) has accepted the filing of a Marketing Authorization Application (MAA) for lorcaserin, an investigational drug candidate intended for weight control, including weight loss and maintenance of weight loss, in patients who are obese (BMI >30) or patients who are overweight (BMI >27) and have at least one weight-related co-morbid condition.
Determining what triggers the death of retinal cells, called photoreceptors, could hold the key to stopping blinding disorders caused by a wide range of eye diseases, Yale School of Medicine researchers report in the November journal Investigative Ophthalmology & Visual Science.
› Verified 1 days ago
Michael Jones, Otolaryngology Medicare: Not Enrolled in Medicare Practice Location: 8900 Van Wyck Expy, Jamaica, NY 11418 Phone: 718-206-7001 | |
Rachel T Irizarry, M.D. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 8268 164th St # 614, Jamaica, NY 11432 Phone: 718-883-4273 |